#givosiran

[sameermi]

Acute Intermittent Porphyria Market Size and Emerging Growth Trends

The Acute Intermittent Porphyria market is witnessing significant developments driven by novel therapeutic advancements and increasing aware

[coherentmicom]

The Acute Intermittent Porphyria market is witnessing significant momentum driven by advances in therapeutics and increased disease awarenes

[amcrasto]

Givosiran, ギボシラン ,

Givosiran

N-[1,3-bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide

Treatment of Acute Hepatic Porphyria…

View On WordPress

[amcrasto]

FDA approves first treatment Givlaari (givosiran) for inherited rare disease

FDA approves first treatment Givlaari (givosiran) for inherited rare disease

Today, the U.S. Food and Drug Administration granted approval to Givlaari (givosiran) for the treatment of adult patients with acute hepatic porphyria, a genetic disorder resulting in the buildup of toxic porphyrin molecules which are formed during the production of heme (which helps bind oxygen in the blood). “This buildup can cause acute attacks, known as porphyria attacks, which can lead to…

View On WordPress